PRNewsWire
18 Mar 2026, 13:00 UTC · 26w ago
Verdict
Headline takes no side. We score GRAL −1.00 across four claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Grail's NHS Galleri randomized trial failed to meet its primary endpoint.
More negative than 99% of claims this week
Grail (GRAL) experienced a market value loss of approximately 50% following the disclosure of the trial results.
So whatA 50% collapse in valuation reflects a severe loss of investor confidence and a massive reset in the company's perceived value.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 97% of claims this week
Law firm Levi & Korsinsky is investigating whether Grail management omitted material headwinds and risks regarding the NHS trial in their forward guidance.
More negative than 85% of claims this week
Grail management previously guided to a cash runway extending into 2030 based on the assumption of meeting clinical and regulatory milestones.
More negative than 70% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company lost 50% of its market value following a failed clinical trial and is facing a securities investigation.
More negative than 87% of ticker scores this week
Shares fell sharply after reporting a significant revenue shortfall against analyst consensus.
More negative than 86% of ticker scores this week
The company is subject to a securities investigation following shareholder losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+125.6%
Price is moving against the score
$106.86 vs $47.37 close before publication (Mar 17) · not market-adjusted
GRAL chart →